Carlos L. Arteaga
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Oncogene signaling and therapeutic resistance to antiestrogens in breast cancer
Open Date: 2024-10-01
Close Date: 2025-09-30
Grant: Close
Combinations of Anti-HER2 Therapies to Eliminate Drug Resistance
Open Date: 2012-07-01
Close Date: 2017-06-30
Grant: Close
HER2 (ErbB2) gene mutations and therapeutic resistance to HER2 inhibitors
Open Date: 2007-07-01
Close Date: 2012-06-30
Articles (31)
Purpose: Activating mutations in AKT genes are rare but play an important role in the commonly dysregulated PI3K/AKT/mTOR signaling pathway in multiple cancers. NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolled patients to targeted therapies based on matching tumor genomic alterations. Subprotocol Z1K evaluated ipatasertib, a pan-AKT inhibitor, in patients with AKT1 E17K -mutant metastatic tumors. Patients and Methods: Patients received ipatasertib 400 mg orally once daily in a 28-day cycle until progression or unacceptable toxicity. Patients with well-controlled diabetes were eligible. Patients with known KRAS , NRAS , HRAS , or BRAF mutations were excluded. Prior PI3K and mTOR inhibitors were allowed. Prior AKT inhibitors were excluded. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival, 6-month progression-free survival, and toxicity. Results: Thirty-five patients were enrolled, and 29 patients were included in the prespecified primary efficacy analysis. Multiple histologies were enrolled, with breast ( n = 18) and gynecologic ( n = 7) being the most common. The majority had >3 lines of prior therapy (19/29; 65.5%). The ORR was 24.1% (7/29; 90% confidence interval, 11.9%–40.6%) with P n = 25), nausea ( n = 13), and hyperglycemia ( n = 9). Grade 3/4 toxicities observed were consistent with reported toxicities for AKT inhibition. Twelve grade 3 events occurred that were thought to be at least possibly related to treatment. Conclusions: The study met its primary endpoint with an ORR of 24.1% ( P AKT1 E17K mutations. See related commentary by Dahmer Tiecher and Schram, p. 4863
Year:
2025
The MYC oncogene is frequently amplified in triple-negative breast cancer (TNBC). Here, we show that MYC suppression induces immune-related hallmark gene set expression and tumor-infiltrating T cells in MYC-hyperactivated TNBCs. Mechanistically, MYC repressed stimulator of interferon genes (STING) expression via direct binding to the STING1 enhancer region, resulting in downregulation of the T-cell chemokines CCL5, CXCL10, and CXCL11. In primary and metastatic TNBC cohorts, tumors with high MYC expression or activity exhibited low STING expression. Using a CRISPR-mediated enhancer perturbation approach, we demonstrated that MYC-driven immune evasion is mediated by STING repression. STING repression induced resistance to PD-L1 blockade in mouse models of TNBC. Finally, a small-molecule inhibitor of MYC combined with PD-L1 blockade elicited a durable response in immune-cold TNBC with high MYC expression, suggesting a strategy to restore PD-L1 inhibitor sensitivity in MYC-overexpressing TNBC.
Year:
2025
Supplementary Figure 9. Difference in baseline maximum VAF for detected somatic alterations. Panel (a) shows the maximum VAF according to the response category in patients with evaluable disease in the overall cohort. Panel (b) shows further stratification according to the treatment subprotocol.
Year:
2025
Purpose: Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. Experimental Design: We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. Results: We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% ( n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. Conclusions: The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies. See related commentary by Russo et al., p. 4217
Year:
2025
Supplementary Table 9. Distribution of different genetic alterations according to response groups in different treatment arms. Shown in the table is the number of patients with molecular alteration in each response category.
Year:
2025
Supplementary Figure 8. Genomic alterations detected in patients treated in subprotocol Z1A enrolling patients with NRAS mutations who received treatment with binimetinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 6. Genomic alterations detected in patients treated in subprotocol S1 enrolling patients with NF1 mutations who received treatment with trametinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 2. Summary of genomic landscape in patients enrolled based on outside laboratory testing who had discordant mutations. Patients are stratified according to the site of tissue biopsy (primary or metastatic site). Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 7. Genetic alterations detected in patients treated in subprotocol W enrolling patients with FGFR pathway alterations who received treatment with AZD4547. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (51)
Lawrence Rubinstein
Statistician
National Cancer Institute
Yu Wang
Staff Scientist
Vanderbilt University Medical Center
Joonbeom Bae
Korea University
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
housheng hansen he
Senior Scientist
-
Zhao Wang
Associate Professor (Tenured)
Baylor College of Medicine
Ariella Hanker
Associate Professor
University of Texas Southwestern Medical Center
Ping Mu
Associate Professor
Yale University
Xiaoling Li
ARS
Yale University
Mark A. Dickson
-
Cheryl Lewis
Associate Professor
University of Texas Southwestern
Todd Aguilera
University of Texas Southwestern Medical Center
Yang-Xin Fu
professor
Tsinghua University
Su Deng
Assistant Professor
Yale University
Jeon Lee
Assistant Professor
University of Texas Southwestern Medical Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Angela DeMichele
University of Pennsylvania
Jeremy Force
Duke University
Justin M. Balko
Vanderbilt University Medical Center
Hong Zhu
-
Elad Sharon
Associate Professor
Harvard University
Arnaldo Marin Valdés
profesor/a
Universidad de Chile
brian lehmann
Research Assistant Professor
Vanderbilt University Medical Center
Benjamin Brown
Assistant Professor
Vanderbilt University
Bret Mobley
Associate Professor
Vanderbilt University Medical Center
Chang-Ching Lin
Assistant Professor
University of Texas Southwestern Medical Center
Robert Gray
Dana-Farber Cancer Institute
Kevin Kalinsky
Emory University
Yuan Yuan
Scripps Research Institute
Erica M. Stringer-Reasor
Associate Professor
The University of Alabama
Abdullah Al Mamun
Assistant Professor
Meharry Medical College
Ben Ho Park
Vanderbilt University Medical Center
Petros Grivas
University of Washington
Ganesh Raj
Professor
University of Texas Southwestern Medical Center
Guanghui Zhu
Assoicate professor
Sichuan University
QI LIU
Vanderbilt University Medical Center
Anthony Davis
Assistant Professor
University of Texas Southwestern Medical Center
Jens Meiler
Vanderbilt University
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Felix Y. Feng
University of California
Han Liang
The University of Texas MD Anderson Cancer Center
kyung-min lee
Assistant professor
Hanyang University
Rolf A. Brekken
University of Texas Southwestern Medical Center
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Yitao Tang
The University of Texas MD Anderson Cancer Center
Mohamed Gouda
The University of Texas MD Anderson Cancer Center
ZHIJIAN CHEN
Professor
University of Texas Southwestern Medical Center
Katherine Marcelain
Associate Professor
Universidad de Chile
Yan Peng
University of Texas Southwestern Medical Center
Tao Wang
The University of Texas MD Anderson Cancer Center
Yunguan Wang
Assistant Professor
Cincinnati Children's Hospital Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.